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 Abstract 
  Background/Aims:   In view of ongoing controversy, we wished to study whether patient char-
acteristics and/or continuous venovenous hemofiltration (CVVH) characteristics contribute to 
the outcome of non-septic critically ill patients with acute kidney injury (AKI).  Methods:  We ret-
rospectively studied 102 consecutive patients in the intensive care unit (ICU) with non-septic 
AKI needing CVVH. Patient and CVVH characteristics were evaluated. Primary outcome was 
mortality up to day 28 after CVVH initiation.   Results:   Forty-four patients (43%) died during the 
28-day period after the start of CVVH. In univariate analyses, non-survivors had more often a 
cardiovascular reason for ICU admission, greater disease acuity/severity and organ failure, low-
er initial creatinine levels, less use of heparin and more use of bicarbonate-based substitution 
fluid. The latter two can be attributed to high lactate levels and bleeding tendency in non-sur-
vivors necessitating withholding lactate-buffered fluid and heparin, respectively, according to 
our clinical protocol. In multivariate analyses, mortality was predicted by disease severity, use 
of bicarbonate-based fluids and lack of heparin, while initial creatinine and CVVH dose did not 
contribute.   Conclusion:   The outcome of non-septic AKI in need of CVVH is more likely to be 
determined by underlying or concurrent, acute and severe disease rather than by CVVH char-
acteristics, including timing and dose.    Copyright © 2011 S. Karger AG, Basel 
  Published online: September 24, 2011 
EXTRA
  S.A. Nurmohamed, MD 
This is an Open Access article licensed under the terms of the Creative Commons Attribution- 
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online 
version of the article only. Distribution for non-commercial purposes only.
  Department of Nephrology, VU University Medical Center 
  PO Box 7057 
  NL–1007 MB Amsterdam (The Netherlands) 
  Tel. +31 20 4442 673, E-Mail sa.nurmohamed    @   vumc.nl 
www.karger.com/nne
 DOI:  10.1159/000331703 92
Nephron Extra 2011;1:91–100
 DOI:  10.1159/000331703 
EXTRA
  Koning et al.: Outcome Determinants in Non-Septic AKI 
www.karger.com/nne
    © 2011 S. Karger AG, Basel
  Published online: September 24, 2011 
 Introduction 
  Acute kidney injury (AKI) is common and associated with a high morbidity and mor-
tality in the critically ill   [1–4]  . Renal replacement therapy is required in about 6% of patients 
and this is associated with a rise in mortality to about 60%   [2, 4, 5]  . Although improved 
therapy might help to decrease survival, the optimal timing, dose and type of renal replace-
ment therapy, such as continuous venovenous hemofiltration (CVVH), the major treatment 
in Europe   [5]  , remain to be determined. Although septic AKI may differ from non-septic 
AKI, and the former may benefit more from higher CVVH dose compared with the latter  [4, 
6–8]  , patients have often been lumped together in prospective randomized trials, and as a 
result, timing, dose and the schedule of renal replacement therapy remain largely inconsis-
tent   [6, 8–17]  . In a retrospective analysis of both septic and non-septic patients, oligoanuria, 
acidosis and concomitant organ dysfunction at the time of initiation of renal replacement 
therapy were associated with high mortality   [18]  . Another observational retrospective study 
also did not reveal an effect of dose  [19] , whereas higher creatinine levels at the start of CVVH 
suggested that late rather than early treatment was of benefit  [7] , being in contrast to prospec-
tive and sometimes even randomized studies  [13, 20–22] . However, treatment guided by urea 
levels did not improve outcome in another prospective randomized study   [15]  . The contra-
dicting results may partly relate to differences in patient recruitment and modes of renal re-
placement therapy across studies. Alternatively, the contribution of CVVH characteristics to 
outcome may be smaller than that of patient characteristics, including type and severity of 
the underlying disease and co-morbidity, but these issues have hardly been addressed in large 
observational studies using different renal replacement therapy modes previously   [5, 18, 19]  . 
Our recent retrospective analysis restricted to sepsis-induced AKI requiring CVVH sug-
gested however that the dose delivered, rather than timing, mode of administration, azo-
temic control and concomitant organ failure, is an independent predictor of outcome   [23]  .
  In the current retrospective study, we aimed to evaluate determinants of a favorable out-
come in critically ill patients with AKI in need of CVVH. In an attempt to minimize differ-
ences attributable to patient selection, only non-septic AKI was studied. Our hypothesis was 
that outcome in non-septic AKI is determined by both patient and CVVH characteristics. 
  Patients  and  Methods 
  All patients treated with CVVH between November 17, 2004, and January 31, 2006, in 
the intensive care unit (ICU) of a university hospital were retrospectively studied. AKI was 
defined as a sudden creatinine and/or urea increase, loss of urine production or decreased 
renal clearance. Exclusion criteria were other indications for CVVH than AKI, such as a last 
known creatinine clearance (or estimated glomerular filtration rate using the abbreviated 
Modification of Diet in Renal Disease formula)  ! 15 ml/min. Patients were excluded from the 
study if criteria of sepsis occurred within a 48-hour window after the start of CVVH. Sepsis 
was considered present if patients had clinical evidence of infection and at least two or more 
of the following conditions; temperature   !  36.0 or   1 38.0   °    C; heart rate   1  90 beats/min; respi-
ratory rate  1 20 breaths/min or mechanical ventilation, and/or white blood cells  ! 4.0 or  1 12.0 
  !   10 9 / l    [2 4] .
  Therapeutic  Protocol 
  Decisions regarding the time of initiation of CVVH were based on the opinion of the 
treating physicians and consulting nephrologists. The decision to start CVVH was based on 
the following parameters: diuresis, plasma urea and creatinine, plasma potassium and bi-93
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carbonate, and the occurrence of fluid overload. Other decisions included the use of anti-
coagulation, substitution fluid (lactate, bicarbonate or citrate buffer;  table 1 ), post- or predi-
lution, ultrafiltration and blood flow rates. To prevent frequent clotting of catheters or fil-
ters, patients were treated per protocol by heparin in order to reach an activated partial 
thromboplastin time of 55–65 s. Patients with increased risk of bleeding complications (de-
fined as a platelet count  ! 40  !  10 9 /l, an activated partial thromboplastin time  1 60 s, a pro-
thrombin time test (INR)   1  2.0, a recent major bleeding or significant active bleeding were 
not administered heparin. These patients were treated with anticoagulant-free CVVH (bi-
carbonate or lactate buffered) until the availability of citrate-based substitution fluid in May 
2005, which then became the first choice of treatment in case of a high bleeding risk. Fur-
thermore, the choice of the substitution fluid, lactate or bicarbonate, was based on the oc-
currence of lactic acidosis. Patients are routinely treated with CVVH with lactate-buffered 
substitution fluid. In case of severe lactic acidosis (serum lactate   1 5 mmol/l), CVVH is per-
formed with bicarbonate-buffered hemofiltration. The clinician almost always chooses 
predilution because of the possible positive effect on filter lifetime. CVVH is performed us-
ing a hemofiltration machine (Diapact; Braun, Melsungen, Germany). Vascular access is 
secured by inserting an 11-french double-lumen catheter (GamCath; Gambro, Hechingen, 
Germany) into one of the three large veins (jugular, femoral or subclavian). In all patients, 
a 1.9-m  2   highly permeable cellulose triacetate hemofilter is used (Nipro UF205; Nissho, 
Osaka, Japan). After 72 h, the filters are considered ineffective and are changed on a routine 
basis. In case of blood clots in the filter, an increased filter membrane pressure, or therapeu-
tic or diagnostic interventions, filters are changed earlier. Blood flow and flow of lactate- or 
bicarbonate-based substitution fluid were historically routinely set at 180 ml/min and 2 l/h, 
respectively, with the ultrafiltrate flow set by the treating physicians. When using citrate-
buffered substitution solution, the blood and substitution fluid flow is set per protocol at 
180 ml/min and 2.4 l/h, respectively. CVVH was predicted to be not needed when diuresis 
and sufficient creatinine clearance had resumed, on clinical grounds and based on labora-
tory measurements, which is a commonly applied policy. If patients were indeed not in need 
of CVVH for   1  48 h, AKI was considered to have recovered. If CVVH had to be resumed 
within 48 h after discontinuation, a second episode of CVVH (after the initial episode) was 
defined. 
  D a t a   C o l l e c t i o n  
  Patient characteristics, including age, gender, weight, height (for body mass index, 
BMI), co-morbidities and cause of AKI, were recorded. Data regarding Acute Physiology 
and Chronic Health Evaluation (APACHE II) and the Sequential Organ Failure Assess-
ment (SOFA) score   [1]   were collected. The latter score was obtained on admission and day 
BH 504 HF 32 Bic HF CitPre
Sodium 140 140 139.9
Potassium 1.5 2.0 3.0
Magnesium 0.5 0.5 0.5
Calcium 1.5 1.75 –
Chloride 103 111.5 104.0
Glucose 11.0 1.0 5.0
Citrate – – 39.9
Bicarbonate – 32.0 –
Lactate 42.0 3.0 –
Table 1. C  omposition of the 
substitution fluids (in mmol/l)94
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0 (day of CVVH initiation). Co-morbid conditions are defined as follows: hypertension – a 
diagnosis of hypertension mentioned in the medical record or the use of blood pressure-
lowering agents; diabetes mellitus – a diagnosis of diabetes mellitus mentioned in the med-
ical record or the use of insulin or oral glucose-lowering agents; chronic renal failure – a 
diagnosis of chronic renal failure mentioned in the medical record, without the need of 
renal replacement therapy (stages 1–4 chronic kidney disease), or chronic obstructive pul-
monary disease – a diagnosis of chronic obstructive pulmonary disease mentioned in the 
medical record or the use of medication for this indication. The reasons for ICU admission 
were grouped as follows: cardiovascular disease, respiratory insufficiency, metabolic de-
rangement, neurological disorders, hematological disorders, liver failure and gastrointes-
tinal surgery. The reasons of AKI were categorized into four groups: prerenal/ischemic, 
contrast, rhabdomyolysis and miscellaneous reasons. Data concerning timing of CVVH 
initiation were retrieved; these include serum creatinine, urea, pH and bicarbonate, potas-
sium and diuresis before CVVH initiation. The following CVVH characteristics were also 
recorded: the mode of CVVH (pre- or postdilution), blood flow, substitution flow, ultra-
filtration flow, type of substitution fluid and of anticoagulation, filter life of all filters used, 
the hours CVVH actually performed, downtime, and prescribed and delivered doses. 
Downtime was defined as the interval that CVVH was prescribed but not applied due to 
circuit clotting or transport to the radiology or operating room. The prescribed and deliv-
ered doses were calculated. The former was defined as the ultrafiltration volume delivered 
per kilogram body weight before admission per hour; it was averaged per day and thus in-
cluded downtime. The delivered dose was calculated by adjusting the prescribed dose for 
downtime.
    To compensate the effluent dose based on losses due to predilution, the ultrafiltration 
flow per hour (Q  uf  ) was adjusted according to the following formula:
	

	
 	

b
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bs
Q6 01H ct
Q
Q6 01H ct Q
 ¯ qq ¡° ¢± q
 ¯ qq  ¡° ¢±
  w h e r e   Q  b   = blood flow (ml/min); Q  s   = substitution flow (ml/h) and Hct = hematocrit.  
  The means for filter life, downtime, flow rate and dose were calculated for each patient 
per CVVH episode and for all episodes together, as well as the percent use of predilution 
CVVH, heparin and the different substitution fluids. A group median percentage of 0 thus 
implies that in most patients the respective mode was not used in all filters per patient.
  Statistical  Analysis 
  Patients were grouped according to survival on day 28 after CVVH initiation. A power 
analysis was not performed for this retrospective analysis, but we estimated a mortality rate 
of 50% for the population in the study interval. The data were often non-normally distrib-
uted (Kolmogorov-Smirnov test: p   !   0.05) and values are therefore summarized as medians 
and interquartile ranges (e.g. for the percentage of filters on certain modes per patient). The 
Mann-Whitney U test was used for continuous variables. For categorical data, Fisher’s exact 
test was used. We performed multiple logistic regression using backward elimination to as-
sess the independent value of initial creatinine and delivered dose to predict 28-day mortal-
ity, including variables reaching statistical significance in univariate analyses (p  !  0.05). The 
odds ratio and its 95% confidence interval (CI) were calculated. Similarly, we performed 
multiple proportional hazards (Cox) regression analysis for survival time and calculated 
hazard ratios (95% CI). We did not include filter time, a major determinant of the dose de-
livered, but forced initial creatinine and CVVH dose into the models. Exact p values are 
given if p   1   0.005, and considered statistically significant if p   !   0.05.95
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  R e s u l t s  
 Patient  Characteristics 
  A hundred and two consecutive patients were included. On day 28, 44 patients (43%) had 
died. Two patients died after ICU discharge within 28 days after the start of CVVH. Six patients 
had a second and 1 patient a third episode of CVVH. Fourteen patients received intermittent 
hemodialysis on the ward after ICU discharge. Outcome groups were comparable except for 
reasons of admission, their disease acuity and severity, and organ failure ( table 2 ). Lactate levels 
were higher, and duration of CVVH and hospitalization shorter in non-survivors.
  CVVH  Characteristics 
    Table 3   shows that in non-survivors, less heparin and lactate-buffered fluids and more 
bicarbonate-buffered fluids were used. Filter life and the number of filters used were de-
creased in non-survivors. Ultrafiltrate was somewhat greater in survivors at similar substi-
tution fluid flows, suggesting greater fluid withdrawal. However, neither the prescribed nor 
Table 2. P  atient characteristics
Survivors 
(n = 58)
Non-survivors 
(n = 44)
p value
Age, years 70.5 (18.0) 69.5 (19.0) 0.71
Females/males  26 (45)/32 (55) 16 (30)/28 (70) 0.15
Body weight, kg 78.5 (18.7) 80.0 (18.7) 0.78
Body mass index 25.4 (4.1) 24.7 (4.7) 0.20
Co-morbidity
Hypertension 31 (53) 12 (27) 0.01
Diabetes mellitus 12 (21) 7 (16) 0.61
COPD 9 (15) 3 (7) 0.22
CRF 8 (14) 5 (11) 0.46
APACHE II 24.5 (7.2) 32.5 (10.7) <0.005
SOFA within 24 h 9.0 (3.0) 10.0 (3.0) 0.01
Elective ICU admission 35 (60) 17 (39) 0.04
Admission after surgery 41 (71) 21 (48) 0.02
Reason for ICU admission 
Cardiovascular disease 24 (41) 24 (55) 0.01
Respiratory insufficiency 12 (21) 16 (36) 0.11
Metabolic derangement 6 (10) 12 (27) 0.03
Neurological disorders 1 (2) 8 (18) 0.01
Hematological disorders 2 (3) 8 (14) 0.03
Liver failure 3 (5) 4 (9) 0.40
Gastrointestinal surgery 2 (3) 2 (4) 0.49
Type of AKI
Prerenal/ischemic 46 (79) 35 (80) 0.81
Contrast 3 (5) 1 (2) 0.46
Rhabdomyolysis 4 (7) 3 (7) 0.99
Miscellaneous 5 (9) 5 (11) 0.65
Mechanical ventilation within 24 h 51 (88) 43 (98) 0.13
Vasoactive drugs within 24 h 45 (78) 37 (84) 0.46
Lactate within 24 h, mmol/l 2.7 (2.9) 6.4 (7.9) <0.005
Hospitalization, days 14.0 (21.0) 5.0 (9.0) <0.005
M edian (SD) or number (%) of patients, where appropriate. COPD = Chronic obstructive pulmonary dis-
ease; CRF = chronic renal failure.96
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the delivered CVVH dose, ranging between 12 and 46 ml/kg/h, differed among outcome 
groups.   Table 4   shows that non-survivors had more severe metabolic acidosis, with similar 
oligoanuria, and initial creatinine and urea levels were lower and decreases occurred less of-
ten during (less prolonged) CVVH.
  Multivariable  Analyses 
  Results of logistic and Cox regression analyses are depicted in   table 5  . In both models, 
initial lactate, changes in creatinine/urea or CVVH dose did not contribute to mortality pre-
diction. In any case, both models suggest that mortality is determined by the underlying 
disease determining the mode of CVVH and anticoagulation rather than by timing, as 
judged from initial creatinine values, and dose. As data from patients with a poor prognosis 
can skew the results, we also analyzed the data after excluding patients who deceased within 
48 h (n = 13). The results, however, p  ^  0.05 were similar regarding predicting contributions 
(p = 0.05 or less) by APACHE II score, and percentage on heparin and bicarbonate, but not 
regarding initial creatinine or CVVH dose. 
Table 3. C  haracteristics of CVVH during the ICU stay [median values (SD)]
Survivors
(n = 58)
Non-survivors 
(n = 44)
p
value
Time from ICU admission to CVVH start, days 2.0 (1.2) 1.0 (1.0) 0.76
SOFA at CVVH initiation 11.0 (3.0) 14.0 (4.0) <0.005
First CVVH episode: duration, h 81.0 (90.5) 44.5 (109.5) <0.005
Filters, n 3.0 (3.2) 1.0 (4.7) 0.01
Mean filter life, h 34.3 (27.7) 20.1 (25.2) 0.01
Mean downtime, h 1.5 (1.8) 0 (2.3) 0.01
Mean blood flow, ml/h 180 (0) 180 (0) 0.42
Mean substitution flow, ml/h 2,020 (332) 2,000 (400) 0.78
Mean ultrafiltration flow, ml/h 2,099 (350) 2,040 (400) 0.04
Percentage on:
Predilution 100 (43) 100 (30) 0.95
Heparin 74 (100) 0 (83) <0.005
Citrate 0 (59) 0 (11) 0.24
Bicarbonate 0 (27) 55 (100) <0.005
Lactate 50 (100) 0 (69) 0.01
Mean prescribed dose, ml/kg/h 23.6 (6.8) 23.4 (6.0) 0.99
Mean delivered dose, ml/kg/h 21.8 (6.7) 22.2 (6.2) 0.36
Total CVVH: duration, h 84 (93) 45 (110) <0.005
Filters, n 3.0 (4.2) 1.0 (4.7) 0.01
Mean filter life, h 33.9 (28.4) 20.1 (25.2) 0.01
Mean downtime, h 1.5 (1.8) 0 (2.3) 0.01
Mean blood flow, ml/h 180 (0) 180 (0) 0.54
Mean substitution flow, ml/h 2,075 (332) 2,000 (400) 0.59
Mean ultrafiltration flow, ml/h 2,108 (347) 2,040 (400) 0.03
Percentage on:
Predilution 100 (40) 100 (30) 0.88
Heparin 74 (100) 0 (83) <0.005
Citrate 0 (59) 0 (11) 0.24
Bicarbonate 0 (23) 55 (100) <0.005
Lactate 59 (100) 0 (84) 0.01
Mean prescribed dose, ml/kg/h 23.5 (6.8) 23.4 (6.0) 0.99
Mean delivered dose, ml/kg/h 21.4 (6.7) 22.2 (6.2) 0.3297
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  Discussion 
  This single-center retrospective study suggests that patient rather than CVVH charac-
teristics contribute to the outcome of non-septic, critically ill patients with AKI on CVVH. 
This contrasts with the beneficial effects of a higher CVVH dose in the septic patients stud-
ied by us recently in the same time frame and with similar methodology   [23]  .
    At the start of CVVH, creatinine and urea levels were higher in survivors than in non-
survivors. Although this suggests that CVVH start was postponed in survivors compared to 
non-survivors, as observed before   [7]  , the difference disappeared in multivariable analyses, 
suggesting that timing was not a determinant of outcome in our patients [cf.   9, 21  ], in con-
trast to suggestions that early institution may improve outcome   [14, 20, 22]  . The lower blood 
pH in non-survivors than in survivors can be attributed to higher lactate levels rather than 
more progressive renal failure. Since, per protocol, bicarbonate-buffered fluid is preferred to 
lactate-buffered fluid in case of lactic acidosis, the use of bicarbonate-buffered fluid predict-
ed mortality in our models, and this is unlikely caused by a detrimental effect of the solution 
Table 4. R  enal metabolism prior to and during CVVH [median values (SD)]
Survivors 
(n = 58)
Non-survivors 
(n = 44)
p
value
Within 24 h prior to CVVH initiation
Diuresis, ml/h 13.7 (16.5) 12.0 (19.7) 0.89
pH 7.26 (0.14) 7.19 (0.15) <0.005
Bicarbonate, mmol/l 17.5 (5.0) 14.0 (4.4) <0.005
Potassium, mmol/l 5.1 (1.1) 5.1 (1.1) 0.94
Creatinine, mol/l 285 (129) 236 (120) 0.01
Urea, mmol/l 17.8 (11.4) 14.2 (13.4) 0.16
During CVVH
Highest creatinine, mol/l 285 (99) 177 (135) 0.01
Lowest creatinine, mol/l 140 (80) 110 (84) 0.20
Change in creatinine, mol/l 130 (117) 32 (123) <0.005
Highest urea, mmol/l 18.5 (10.9) 10.3 (12.5) 0.04
Lowest urea, mmol/l 9.9 (5.6) 10.3 (10.9) 0.82
Change in urea, mmol/l 5.7 (12.1) 1.0 (2.7) 0.04
Table 5. M  ultivariable (logistic and Cox regression) analyses of determinants of mortality in non-septic 
AKI patients needing CVVH
Odds ratio 
(95% CI)
p
value
Hazard ratio
(95% CI)
p
value
APACHE II 1.16 (1.06–1.27) 0.001 1.09 (1.04–1.14) 0.001
Initial creatinine, mol/l 0.99 (0.99–1.00) 0.18 0.99 (0.99–1.11) 0.14
On heparin 0.98 (0.96–0.99) 0.007 0.99 (0.99–1.00) 0.04
Substitution fluid
Lactate buffered 1.02 (1.00–1.04) 0.04 not calculated 0.25
Bicarbonate buffered 1.03 (1.01–1.05) 0.003 1.01 (0.99–1.01) 0.03
Delivered dose of CVVH, ml/kg/h 1.10 (0.99–1.21) 0.07 not calculated 0.25
F  or logistic regression: Hosmer-Lemeshow test 2 7.4, d.f. 8, p = 0.50, indicating good calibration.98
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itself   [25]  . The absence of anticoagulation with heparin also predicted mortality, which is 
withheld in case of a bleeding tendency, which may be more severe in non-survivors. We 
cannot exclude that this contributed to the lower survival times of filters in non-survivors or 
that heparin has even exerted beneficial effects in our non-septic patients. The greater fall in 
creatinine and urea levels in survivors can be explained by the longer duration of CVVH. 
Downtime was decreased in non-survivors, which may be explained by the fact that in many 
patients in this group only one filter was used, which results in zero downtime. 
    Taken together, our results suggest that CVVH characteristics such as timing, dose and 
azotemic control did not determine outcome, while crude outcome and its patient-specific 
determinants of our study cohort roughly agree with other studies   [1–5, 18, 19, 22]  . While 
large prospective studies either suggest or deny a benefit of higher- compared to standard-
dose CVVH, many studies suggest that high-dose CVVH more likely benefits septic than 
non-septic patients, as judged from post hoc analyses, in the absence of prior stratified ran-
domization   [6, 8]  . Hence, a higher dose may, in line with observational studies   [26]   and our 
own results   [23]  , potentially be of benefit in septic patients with AKI only. Although under-
dosing (  !  20 ml/kg/h) is a potential threat   [16, 23]  , this may, apparently, not have substan-
tially affected outcome in our non-septic patients.
    Obviously, the limitations of our study include its retrospective nature and the relative-
ly small number of patients, so that conclusions should be drawn cautiously and a small ef-
fect of CVVH characteristics on outcome cannot completely be excluded. They nevertheless 
represent a ‘real-life’ situation in a patient cohort treated with a single renal replacement 
therapy mode, and the observations may help to design and power future studies investigat-
ing timing and dose of CVVH in the critically ill. The results did not prompt us to change 
current CVVH practice for non-septic patients.
    In conclusion, our retrospective data suggest that patient characteristics rather than the 
timing, dose and mode of CVVH and azotemic control are predominant determinants of 
outcome in critically ill non-septic patients with AKI. 
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